{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:42:12Z","timestamp":1788176532541,"version":"build-2803163510"},"reference-count":49,"publisher":"Academy of Medicine, Singapore","issue":"1","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Acad Med Singap"],"published-print":{"date-parts":[[2025,1,23]]},"abstract":"<jats:p>Introduction: Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is a curative option for relapse\/refractory (R\/R) lymphomas that have failed autologous transplantation or for high-risk lymphomas in the upfront setting. We conducted a retrospective analysis on consecutive lymphoma patients who underwent allo-HSCT over a 20-year period (2003\u2013 2022) at Singapore General Hospital and National University Hospital Singapore. \n\nMethod: A total of 121 patients were included in the study. Median age was 41 years. Diagnoses include Hodgkin lymphoma (HL, 15%), B-cell non- Hodgkin lymphoma (B-NHL, 34%), T-cell non-Hodgkin lymphoma (T-NHL, 31%) and natural killer T-cell lymphoma (NKTL, 20%). Moreover, 27% of patients had prior auto-haematopoietic stem cell transplanta-tion (auto-HSCT), and 84% received reduced intensity conditioning (RIC). Donor types were matched sibling donor (45%), matched unrelated donor (29%), haploidentical donor (19%) and cord blood (CB, 7%). \n\nResults: After median follow-up of 56 months, estimated 4-year progression-free survival (PFS) and overall survival (OS) for all patients were 38% and 45%, respectively. Non-relapse mortality (NRM) was 15% at day 100 and 24% at 1 year. On univariate analysis, complete remission status at transplant and RIC confers superior OS. On multivariate analysis, HL was associated with superior OS compared to NHL, whereas matched unrelated donor transplant was associated with significantly inferior OS compared to matched sibling donor. \n\nConclusion: Long-term curative durability was observed with allo-HSCT for patients with relapsed\/ refractory lymphomas. This real-world data serves as a valuable historical benchmark for future studies on lymphomas in Singapore and the Asia Pacific region.<\/jats:p>","DOI":"10.47102\/annals-acadmedsg.2024178","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T08:25:27Z","timestamp":1737620727000},"page":"5","source":"Crossref","is-referenced-by-count":2,"title":["Long-term survival and clinical implications of allogeneic stem cell transplantation in relapse\/refractory lymphoma: A 20-year Singapore experience"],"prefix":"10.47102","volume":"54","author":[{"given":"Wei Sheng Joshua","family":"Loke","sequence":"first","affiliation":[{"name":"Tan Tock Seng Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Rachel","family":"Catapia","sequence":"additional","affiliation":[{"name":"National University Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chay Lee","family":"Low","sequence":"additional","affiliation":[{"name":"Singapore General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Lim","sequence":"additional","affiliation":[{"name":"Singapore General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Quek","sequence":"additional","affiliation":[{"name":"Singapore General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hein","family":"Than","sequence":"additional","affiliation":[{"name":"Singapore General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeow Tee","family":"Goh","sequence":"additional","affiliation":[{"name":"Singapore General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeh Ching","family":"Linn","sequence":"additional","affiliation":[{"name":"Singapore General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin Phipps","family":"Diong","sequence":"additional","affiliation":[{"name":"Singapore General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aloysius","family":"Ho","sequence":"additional","affiliation":[{"name":"Singapore General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Hwang","sequence":"additional","affiliation":[{"name":"Singapore General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung Cheng Jordan","family":"Hwang","sequence":"additional","affiliation":[{"name":"Singapore General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Singapore General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang Pui","family":"Koh","sequence":"additional","affiliation":[{"name":"Singapore General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lip Koon","family":"Tan","sequence":"additional","affiliation":[{"name":"National University Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Lee","sequence":"additional","affiliation":[{"name":"National University Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li Mei Michelle","family":"Poon","sequence":"additional","affiliation":[{"name":"National University Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng Kiat Lawrence","family":"Ng","sequence":"additional","affiliation":[{"name":"Singapore General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26165","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Mamez AC, Dupont A, Blaise D, et al. Allogeneic stem cell transplantation for peripheral T cell lymphomas: a retrospective study in 285 patients from the Soci\u00e9t\u00e9 Franco-phone de Greffe de Moelle et de Th\u00e9rapie Cellulaire (SFGM-TC). J Hematol Oncol 2020;13:56. DOI: 10.1186\/s13045-020-00892-4","DOI":"10.1186\/s13045-020-00892-4"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Corradini P, Dodero A, Farina L, et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia 2007;21: 2316-23. DOI: 10.1038\/sj.leu.2404822","DOI":"10.1038\/sj.leu.2404822"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Schmitz N, Lenz G, Stelljes M. Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas. Blood 2018;132:245-53. DOI: 10.1182\/blood-2018-01-791335","DOI":"10.1182\/blood-2018-01-791335"},{"key":"ref3","unstructured":"Sureda A, Canals C, Arranz R, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin\u2019s lymphoma."},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Results of the HDR-ALLO study-a prospective clinical trial by the Grupo Espa\u00f1ol de Linfomas\/ Trasplante de M\u00e9dula Osea (GEL\/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2012;97:310-7. DOI: 10.3324\/haematol.2011.045757","DOI":"10.3324\/haematol.2011.045757"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Bento L, Guti\u00e9rrez A, Novelli S, et al. Allogeneic stem cell transplantation as a curative option in relapse\/refractory diffuse large B cell lymphoma: Spanish multicenter GETH\/ GELTAMO study. Bone Marrow Transplant 2021;56:1919-28. DOI: 10.1038\/s41409-021-01264-3","DOI":"10.1038\/s41409-021-01264-3"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Burroughs LM, O\u2019Donnell PV, Sandmaier BM, et al. Comparison of Outcomes of HLA-Matched Related, Unrelated, or HLA-Haploidentical Related Hematopoietic Cell Transplan-tation following Nonmyeloablative Conditioning for Relapsed or Refractory Hodgkin Lymphoma. Biol Blood Marrow Transplant 2008;14:1279-87. DOI: 10.1016\/j.bbmt.2008.08.014","DOI":"10.1016\/j.bbmt.2008.08.014"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Fenske TS, Hamadani M, Cohen JB, et al. Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients. Biol Blood and Marrow Transplant 2016;22:1543-51. DOI: 10.1016\/j.bbmt.2016.04.019","DOI":"10.1016\/j.bbmt.2016.04.019"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25:579-86. DOI: 10.1200\/JCO.2006.09.2403","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014;32:3059-67. DOI: 10.1200\/jco.2013.54.8800","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Berning P, Fekom M, Ngoya M, et al. Hematopoietic stem cell transplantation for DLBCL: a report from the European Society for Blood and Marrow Transplantation on more than 40,000 patients over 32 years. Blood Cancer J 2024;14:106. DOI: 10.1038\/s41408-024-01085-9","DOI":"10.1038\/s41408-024-01085-9"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Baek DW, Moon JH, Lee JH, et al. Real-world data of long-term survival in patients with T-cell lymphoma who underwent stem cell transplantation. Blood Cancer J 2023;13:95. DOI: 10.1038\/s41408-023-00868-w","DOI":"10.1038\/s41408-023-00868-w"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Leen AM, Heslop HE, Brenner MK. Antiviral T-cell therapy. Immunol Rev 2014;258:12-29. DOI: 10.1111\/imr.12138","DOI":"10.1111\/imr.12138"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Schaffrath J, Brummer C, Wolff D, et al. High Mortality of COVID-19 Early after Allogeneic Stem Cell Transplantation: A Retrospective Multicenter Analysis on Behalf of the German Cooperative Transplant Study Group. Transplant Cell Ther 2002;28:337.e1-337.e10. DOI: 10.1016\/j.jtct.2022.03.010","DOI":"10.1016\/j.jtct.2022.03.010"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Busca A, Salmanton-Garc\u00eda J, Marchesi F, et al. Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry. Front Immunol 2023;14:1125030. DOI: 10.3389\/fimmu.2023.1125030","DOI":"10.3389\/fimmu.2023.1125030"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Hakki M, Atiken SL, Danziger-Isakov L, et al. American Society for Transplantation and Cellular Therapy Series: #3\u2014 Prevention of Cytomegalovirus Infection and Disease After Hematopoietic Cell Transplantation. Transplant Cell Ther 2021;27:707-19. DOI: 10.1016\/j.jtct.2021.05.001","DOI":"10.1016\/j.jtct.2021.05.001"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Tan CA, Palen L, Su Y, et al. Impact of Primary Letermovir Prophylaxis Versus Preemptive Antiviral Therapy for Cytomegalovirus on Economic and Clinical Outcomes after Hematopoietic Cell Transplantation. Transplant Cell Ther 2024;30:792.e1-792.e12. DOI: 10.1016\/j.jtct.2024.05.021","DOI":"10.1016\/j.jtct.2024.05.021"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Hamadani M, Saber W, Ahn KW, et al. Impact of pretrans-plantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma. Biol Blood Marrow Transplant 2013;19:746-53. DOI: 10.1182\/blood.v120.21.473.473","DOI":"10.1016\/j.bbmt.2013.01.024"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Kharfan-Dabaja MA, Reljic T, El-Asmar J, et al. Reduced-intensity or myeloablative allogeneic hematopoietic cell transplantation for mantle cell lymphoma: a systematic review. Future Oncol 2016;12:2631-42. DOI: 10.2217\/fon-2016-0146","DOI":"10.2217\/fon-2016-0146"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Bacher U, Klyuchnikov E, Le-Rademacher J, et al. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? Blood 2012;120:4256-62. DOI: 10.1182\/blood-2012-06-436725","DOI":"10.1182\/blood-2012-06-436725"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Hamadani M, Ngoya M, Sureda A, et al. Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics. Blood Adv 2022;6:920-30. DOI: 10.1182\/bloodadvances.2021005899","DOI":"10.1182\/bloodadvances.2021005899"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Landry I. Racial disparities in hematopoietic stem cell transplant: a systematic review of the literature. Stem Cell Investig 2021;8:24. DOI: 10.21037\/sci-2021-058","DOI":"10.21037\/sci-2021-058"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Kekre N, Antin JH. ATG in allogeneic stem cell transplantation: standard of care in 2017? Counterpoint. Blood Adv 2017;9:573-6. DOI: 10.1182\/bloodadvances.2016001552","DOI":"10.1182\/bloodadvances.2016001552"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Bonifazi F, Rubio MT, Bacigalupo A, et al. Rabbit ATG\/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel. Bone Marrow Transplant 2020;55:1093-1102. DOI: 10.1038\/s41409-020-0792-x","DOI":"10.1038\/s41409-020-0792-x"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Kennedy VE, Chen H, Savani BN, et al. Optimizing Antithymocyte Globulin Dosing for Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Based on Recipient Absolute Lymphocyte Count. Biol Blood and Marrow Transplant 2018;24:150-5. DOI: 10.1016\/j.bbmt.2017.08.029","DOI":"10.1016\/j.bbmt.2017.08.029"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Brissot E, Labopin M, Labussi\u00e8re H, et al. Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplan-tation in recipients of matched sibling or 10\/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial. Blood Cancer J 2024;14:31. DOI: 10.1038\/s41408-024-00990-3","DOI":"10.1038\/s41408-024-00990-3"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Dachy F, Furst S, Calmels B, et al. GVHD prophylaxis with post-transplant cyclophosphamide results in lower incidence of GVHD and allows faster immunosuppressive treatment reduction compared to antithymocyte globulin in 10\/10 HLA-matched unrelated allogeneic hematopoietic cell transplan-tation. Bone Marrow Transplant 2023;58:1179-81. DOI: 10.1038\/s41409-023-02033-0","DOI":"10.1038\/s41409-023-02033-0"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Chalandon Y, Eikema DJ, Moiseev I, et al. Unrelated donor transplantation with posttransplant cyclophosphamide vs ATG for myelodysplastic neoplasms. Blood Adv 2024; 8:4792-4802. DOI: 10.1182\/bloodadvances.2024013468","DOI":"10.1182\/bloodadvances.2024013468"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Montoro J, Boumendil A, Finel H, et al. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplantation for Patients with Hodgkin Lymphoma: A Comparative Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. Transplant Cell Ther 2024;30:210.e1-210.e14. DOI: 10.1016\/j.jtct.2023.11.021","DOI":"10.1016\/j.jtct.2023.11.021"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Izutsu K, Ishitsuka K, Maruyama D, et al. Valemetostat for Relapsed or Refractory B-Cell Lymphomas: Primary Results from a Phase 1 Trial. Blood 2023;142:1731. DOI: 10.1182\/blood-2023-179301","DOI":"10.1182\/blood-2023-179301"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Izutsu K, Makita S, Nosaka K, et al. An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia\/lymphoma. Blood 2023;141:1159-68. DOI: 10.1182\/blood.2022016862","DOI":"10.1182\/blood.2022016862"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Al-Juhaishi T, Borogovac A, Ibrahimi S, et al. Reappraising the Role of Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Hodgkin\u2019s Lymphoma: Recent Advances and Outcomes. J Pers Med 2022;12:125. DOI: 10.3390\/jpm12020125","DOI":"10.3390\/jpm12020125"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Rashidi A, Ebadi M, Cashen AF. Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis. Bone Marrow Transplant 2016; 51:521-8. DOI: 10.1038\/bmt.2015.332","DOI":"10.1038\/bmt.2015.332"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"El Cheikh J, Massoud R, Abudalle I, et al. Nivolumab salvage therapy before or after allogeneic stem cell transplantation in Hodgkin lymphoma. Bone Marrow Transplant 2017; 52:1074-7. DOI: 10.1038\/bmt.2017.69","DOI":"10.1038\/bmt.2017.69"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Herbaux C, Merryman R, Devine S, et al. Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: Taming a necessary evil. Blood 2018;132:9-16. DOI: 10.1182\/blood-2018-02-811174","DOI":"10.1182\/blood-2018-02-811174"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Merryman RW, Castagna L, Giordano L, et al. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia 2021;35:2672-83. DOI: 10.1038\/s41375-021-01193-6","DOI":"10.1038\/s41375-021-01193-6"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Schmitz N, Truemper L, Bouabdallah K, et al. A randomized phase 3 trial of auto vs. allo transplantation as part of first-line therapy in poor-risk peripheral T-NHL. Blood 2021;137:2646-56. DOI: 10.1182\/blood.2020008825","DOI":"10.1182\/blood.2020008825"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Kwong YL, Anderson BO, Advani R, et al. Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009;10:1093-101. DOI: 10.1016\/s1470-2045(09)70265-7","DOI":"10.1016\/S1470-2045(09)70265-7"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Murashige N, Kami M, Kishi Y, et al. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br J Haematol 2005;130:561-7. DOI: 10.1111\/j.1365-2141.2005.05651.x","DOI":"10.1111\/j.1365-2141.2005.05651.x"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Tse E, Chan TSY, Koh LP, et al. Allogeneic haematopoietic SCT for natural killer\/T-cell lymphoma: a multicentre analysis from the Asia Lymphoma Study Group. Bone Marrow Transplant 2014;49:902-6. DOI: 10.1038\/bmt.2014.65","DOI":"10.1038\/bmt.2014.65"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Yan Z, Yao S, Wang Z, et al. Treatment of extranodal NK\/T-cell lymphoma: From past to future. Front Immunol 2023;14:1088685. DOI: 10.3389\/fimmu.2023.1088685","DOI":"10.3389\/fimmu.2023.1088685"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Rezvani AR, Norasetthada L, Gooley T, et al. Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. Br J Haematol 2008;143:395-403. DOI: 10.1111\/j.1365-2141.2008.07365.x","DOI":"10.1111\/j.1365-2141.2008.07365.x"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Robinson SP, Goldstone AH, Mackinnon S, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002;100:4310-6. DOI: 10.1182\/blood-2001-11-0107","DOI":"10.1182\/blood-2001-11-0107"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol 2019;20:31-42. DOI: 10.3410\/f.734570341.793562630","DOI":"10.3410\/f.734570341.793562630"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Neelapu SS, Jacobson CA, Ghobadi A, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood 2023;141:2307-15. DOI: 10.1182\/blood-2023-174288","DOI":"10.1182\/blood-2023-174288"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Bethge WA, Martus P, Schmitt M, et al. GLA\/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany. Blood 2022;140:349-58. DOI: 10.1182\/blood.2021015209","DOI":"10.1182\/blood.2021015209"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Zurko J, Ramdial J, Shadman M, et al. Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma. Haematologica 2023;108:98-109. DOI: 10.3324\/haematol.2022.281242","DOI":"10.3324\/haematol.2022.281242"},{"key":"ref47","unstructured":"The Straits Times. Government subsidies now available for cell, tissue and gene therapy in Singapore, 2024. https:\/\/www.straitstimes.com\/singapore\/health\/governmentsubsidies-now-available-for-cell-tissue-and-gene-therapy-insingapore. Accessed 30 October 2024."},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med 2022;386:640-54. DOI: 10.1056\/NEJMoa2116133","DOI":"10.1056\/NEJMoa2116133"}],"container-title":["Annals of the Academy of Medicine, Singapore"],"original-title":[],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:25:58Z","timestamp":1782275158000},"score":1,"resource":{"primary":{"URL":"https:\/\/annals.edu.sg\/long-term-survival-and-clinical-implications-of-allogeneic-stem-cell-transplantation-in-relapse-refractory-lymphoma-a-20-year-singapore-experience"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,23]]},"published-print":{"date-parts":[[2025,1,23]]}},"URL":"https:\/\/doi.org\/10.47102\/annals-acadmedsg.2024178","relation":{},"ISSN":["0304-4602"],"issn-type":[{"value":"0304-4602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]}}}